Diabetes, Obesity and Metabolism

Cover image for Vol. 18 Issue 10

Accepted Articles (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

Edited By: R. Donnelly and A. Garber

Impact Factor: 6.198

ISI Journal Citation Reports © Ranking: 2015: 13/131 (Endocrinology & Metabolism)

Online ISSN: 1463-1326

VIEW

  1. 1 - 16
  1. REVIEW ARTICLES

    1. COULD METFORMIN BE USED IN PATIENTS WITH DIABETES AND ADVANCED CHRONIC KIDNEY DISEASE?

      Tahseen A. Chowdhury, Danushan Srirathan, Georgi Abraham, Elizabeth L. Oei, Stanley L. Fan, Kieran McCafferty and M. Magdi Yaqoob

      Accepted manuscript online: 30 SEP 2016 07:35AM EST | DOI: 10.1111/dom.12799

  2. ORIGINAL ARTICLES

    1. Assessing the Real World Effect of Laparoscopic Bariatric Surgery on the Management of Obesity-Related Comorbidities - A Retrospective Matched Cohort Study using a U.S. Claims Database

      Anuprita Patkar, Elliott Fegelman, Sangeeta Kashyap, Stacy Brethauer, Eric Bour, Andrew Yoo and Gang Li

      Accepted manuscript online: 29 SEP 2016 10:20AM EST | DOI: 10.1111/dom.12798

    2. Effect of GLP-1 Receptor Agonist Treatment on Body weight in Obese Antipsychotic-treated Patients with Schizophrenia: a Randomized, Placebo-controlled Trial Byline

      Pelle L. Ishøy, Filip K. Knop, Brian V. Broberg, Nikolaj Bak, Ulrik B. Andersen, Niklas R. Jørgensen, Jens J. Holst, Birte Y. Glenthøj and Bjørn H. Ebdrup

      Accepted manuscript online: 26 SEP 2016 09:45AM EST | DOI: 10.1111/dom.12795

    3. Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): a double-blind, randomized, placebo-controlled clinical trial

      Tracy S Moreira-Lucas, Alison M Duncan, Remi Rabasa-Lhoret, Reinhold Vieth, Alison L Gibbs, Alaa Badawi and Thomas MS Wolever

      Accepted manuscript online: 26 SEP 2016 09:45AM EST | DOI: 10.1111/dom.12794

    4. Near-normalisation of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes

      P. Mensberg, S. Nyby, P. G. Jørgensen, H. Storgaard, M. T. Jensen, J. Sivertsen, J. J. Holst, B. Kiens, E. A. Richter, F. K. Knop and T. Vilsbøll

      Accepted manuscript online: 26 SEP 2016 09:45AM EST | DOI: 10.1111/dom.12797

  3. LETTERS TO THE EDITOR

    1. First metreleptin treatment for generalized lipodystrophy in Turkey

      Ilgın Yildirim Simsir, Banu Sarer Yurekli, Fusun Saygili, Canan Altay and Baris Akinci

      Accepted manuscript online: 26 SEP 2016 09:45AM EST | DOI: 10.1111/dom.12796

  4. ORIGINAL ARTICLES

    1. Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease

      Ella Zomer, Rachel Leach, Christine Trimmer, Tim Lobstein, Stephen Morris, William Philip James and Nick Finer

      Accepted manuscript online: 20 SEP 2016 09:55AM EST | DOI: 10.1111/dom.12792

  5. REVIEW ARTICLES

    1. Glucagon in the artificial pancreas systems; potential benefits and safety profile of future chronic use

      Nadine Taleb, Ahmad Haidar, Virginie Messier, Véronique Gingras, Laurent Legault and Rémi Rabasa-Lhoret

      Accepted manuscript online: 15 SEP 2016 04:23AM EST | DOI: 10.1111/dom.12789

  6. ORIGINAL ARTICLES

    1. Addition or Switch to Insulin Therapy in People Treated with GLP-1 Receptor Agonists: A Real World Study in 66,583 Patients

      Olga Montvida, Kerenaftali Klein, Sudhesh Kumar, Kamlesh Khunti and Sanjoy K Paul

      Accepted manuscript online: 15 SEP 2016 04:23AM EST | DOI: 10.1111/dom.12790

    2. Evaluation of the Efficacy, Safety, and Glycaemic Effects of Evolocumab (AMG 145) in Hypercholesterolaemic Patients Stratified by Glycaemic Status and Metabolic Syndrome

      Dirk J. Blom, Michael J. Koren, Eli Roth, Maria Laura Monsalvo, C. Stephen Djedjos, Patric Nelson, Mary Elliott, Scott M. Wasserman, Christie M. Ballantyne and Rury R. Holman

      Accepted manuscript online: 13 SEP 2016 02:10AM EST | DOI: 10.1111/dom.12788

    3. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: a double-blind randomized controlled trial (INICOM study)

      Soo Lim, Kyung Ah Han, Jae Myung Yu, Parinya Chamnan, Eun Sook Kim, Kun-Ho Yoon, Sam Kwon, Min Kyong Moon, Kwan Woo Lee, Dong-Jun Kim, Mikyung Kim, Manaj Wongtanate, Eun Young Kim, Sung-Ho Kim, Moon-Kyu Lee and INICOM Study Group

      Accepted manuscript online: 13 SEP 2016 01:46AM EST | DOI: 10.1111/dom.12787

    4. Sitagliptin and Risk of Fractures in Type 2 Diabetes: Results from the TECOS Trial

      Robert G. Josse, Sumit R. Majumdar, Yinggan Zheng, Amanda Adler, M. Angelyn Bethel, John B. Buse, Jennifer B. Green, Keith D. Kaufman, Helena Wachslicht Rodbard, Tsvetalina Tankova, Cynthia M. Westerhout, Eric D. Peterson, Rury R. Holman, Paul W. Armstrong and on behalf of the TECOS Study Group

      Accepted manuscript online: 8 SEP 2016 08:55AM EST | DOI: 10.1111/dom.12786

  7. LETTERS TO THE EDITOR

    1. Preference in time of insulin injection in type 2 diabetic patients treated with once-daily long-acting insulin analog

      Mitsuyoshi Takahara, Toshihiko Shiraiwa, Naoto Katakami, Taka-aki Matsuoka and Iichiro Shimomura

      Accepted manuscript online: 9 AUG 2016 03:26AM EST | DOI: 10.1111/dom.12762

  8. EDITORIAL

    1. You have full text access to this OnlineOpen article
      Hepatopreferential insulins: Is this the end or the end of the beginning?

      David Lowell Russell-Jones

      Accepted manuscript online: 5 AUG 2016 01:46AM EST | DOI: 10.1111/dom.12756

  9. REVIEW ARTICLES

VIEW

  1. 1 - 16

SEARCH

SEARCH BY CITATION